Pharmacological treatments for substance use disorders

Journal of Psychosocial Nursing and Mental Health Services

Volumn 42, Issue 8, 2004, Pages 14-20

  Bailey, Katharine P ^a  

^a Clinical Affairs   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUPRENORPHINE; DISULFIRAM; DRUGS USED IN THE TREATMENT OF ADDICTION; METHADONE; NALTREXONE; NARCOTIC AGENT; NARCOTIC ANTAGONIST;

ADDICTION; HUMAN; METHODOLOGY; NEUROBIOLOGY; NEUROPHARMACOLOGY; PSYCHOPHARMACOLOGY; REVIEW; WITHDRAWAL SYNDROME;

ADRENERGIC BETA-ANTAGONISTS; ALCOHOL DETERRENTS; ANTI-ANXIETY AGENTS; BENZODIAZEPINES; BUPRENORPHINE; DISULFIRAM; HUMANS; METHADONE; NALTREXONE; NARCOTIC ANTAGONISTS; NARCOTICS; NEUROBIOLOGY; NEUROPHARMACOLOGY; PSYCHOPHARMACOLOGY; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANCE-RELATED DISORDERS;

EID: 4644281978     PISSN: 02793695     EISSN: None     Source Type: Journal    
DOI: 10.3928/02793695-20040801-03     Document Type: Review

References (34)

1. Amass, L., Kamien, J.B., & Mikulich, S.K. (2001). Thrice-weekly supervised dosing with the combination buprenorphine/naloxone tablet is preferred to daily supervised dosing by opioid-dependent humans. Drug & Alcohol Dependence, 61, 173-181.
2. th ed.). Washington, DC: Author.
3. American Psychiatric Association. (2000). Practice guidelines for the treatment of psychiatric disorders compendium 2000. Washington, DC: Author.
4. Anton, R.F. (2001). Pharmacologic approaches to the management of alcoholism. Journal of Clinical Psychiatry, 62(Suppl. 20), ll-17.
5. Anton, R.F., Moak, D.H., Waid, L.R., Latham, P.K., Malcolm, R.J., & Dias, J.K. (1999). Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: Results of a placebo-controlled trial. American Journal of Psychiatry, 156, 1758-1764.
6. Bailey, K.P. (2004). The brain's rewarding system and addiction. Journal of Psychosocial Nursing and Mental Health Services, 42(6), 14-18.
7. Ciraulo, D.A., & Shader, R.I. (1991). Clinical manual of chemical dependence. Washington, DC: American Psychiatric Press.
8. Cornish, J.W., McNicholas, L.F., & O'Brien, C.P. (1998). Treatment of substance-related disorders. In A.F. Schatzberg &C.B. Nemeroff (Eds.), The American Psychiatric Press textbook of psychopharmacology. Washington, DC: American Psychiatric Press.
9. Froehlich, J.C., Harts, J., Lumeng, L., & Li, T.K. (1990). Naloxone attenuates voluntary ethanol intake in rats selectively bred for high ethanol preference. Pharmacology, Biochemistry, and Behavior, 35, 385-390.
10. Fuller, R.K., Branchey, L., Brightwell, D.R., Derman, R.M., Emrick, C.D., Iber, F.L., & et al. (1986). Disulfiram treatment of alcoholism: A Veterans Administration cooperative study. Journal of the American Medical Association, 256, 1449-1455.
11. Johnson, B.A., Jasinski, D.R., Galloway, G.P., Kranzler, H., Weinreib, R., Anton, R.F., et al. (1996). Ritanserin in the treatment of alcohol dependence: A multi-center clinical trial. Ritanserin Study Group. Psychopharmacology (Berlin), 128, 206-215.
12. Kintz, P. (2001). Deaths involving buprenorphine: a compendium of French cases. Forensic Science International, 121, 65-69.
13. Kosten, T.R., Morgan, C., & Kleber, H.D. (1991). Treatment of heroin addicts using buprenorphine. American Journal of Drug & Alcohol Abuse, 17, 119-28.
14. Kranzler, H.R., Bauer, L.O., Hersh, D., & Klinghoffer, V. (1995). Carbamazepine treatment of cocaine dependence: A placebo-controlled trial. Drug and Alcohol Dependence, 38, 203-211.
15. Kranzler, H.R., Burleson, J.A., Korner, P., Del Boca, F.K., Bohn, M.J., Brown, J., et al. (1995). Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. American Journal of Psychiatry, 152, 391-397.
16. rd ed.). Baltimore, MD: Williams and Wilkins.
17. Mason, B.J. (2001). Treatment of alcohol-dependent outpatients with acamprosate: A clinical review. Journal of Clinical Psychiatry, 62(Suppl. 20), 42-48.
18. Montoya, I.D., Levin, F.R., Fudala, P.J., & Gorelick, D.A. (1995). Double-blind comparison of carbamazepine and placebo for treatment of cocaine dependence. Drug and Alcohol Dependence, 38, 213-219.
19. O'Malley, S.S., Jaffe, A.J., Chang, G., Schottenfeld, R.S., Meyer, R.E., & Rounsaville, B. (1992). Naltrexone and coping skills therapy for alcohol dependence: A controlled study. Archives of General Psychiatry, 49, 881-887.
20. Resnick, R.B., Galanter, M., Pycha, C., Cohen, A., Grandison, P., & Flood, N. (1992). Buprenorphine: An alternative to methadone for heroin dependence treatment. Psychopharmacology Bulletin, 28, 109-113.
21. Saitz, R., Mayo-Smith, M.F., Roberts, M.S., Redmond, H.A., Bernard, D.R., & Calkins, D.R. (1994). Individualized treatment for alcohol withdrawal. Journal of the American Medical Association, 272, 519-523.
22. Sass, H., Soyka, M., Mann, K., & Zeiglgansberger, W. (1996). Relapse prevention by acamprosate: Results from a placebo-controlled study on alcohol dependence. Archives of General Psychiatry, 53, 673-680.
23. Shader, R.I. (2003). Manual of psychiatric therapeutics. Philadelphia: Lippincott Williams and Wilkins.
24. Substance Abuse and Mental Health Services Administration. (2001). Final rule. Fed Reg 66(11), 4076-4102, 1-17.
25. Thase, M.E., Salloum, I.M., & Cornelius, J.D. (2001). Comorbid alcoholism and depression: Treatment issues. Journal of Clinical Psychiatry, 62(Suppl. 20), 32-41.
26. Tracqui, A., Kintz, P., & Ludes, B. (1998). Buprenorphine-related deaths among drug addicts in France: A report on 20 fatalities. Journal of Analytical Toxicology, 22, 430-433.
27. Umbricht, A., Montoya, I.D., Hoover, D.R., Demuth, K.L., Chiang, C.T., & Preston, K.L. (1999). Naltrexone shortened opioid detoxification with buprenorphine. Drug and Alcohol Dependence, 56, 181-190.
28. U.S. Food and Drug Administration. (2001, March). ORLAAM oral solution. In Index of safety-related drug labeling change summaries approved by FDA Center for Drug Evaluation and Research Retrieved July 12, 2004, from http://www.fda.gov/medwatch/ safety/2001/mar01.htm#orlaam
29. Volpicelli, J.R., Alterman, A.I., Hayashida, M., & O'Brien, C.P. (1992). Naltrexone in the treatment of alcohol dependence. Archives of General Psychiatry, 49, 876-880.
30. Volpicelli, J.R., Rhines, K.C., Rhines, J.S., Volpicelli, L.A., Alterman, A.I., & O'Brien, C.P. (1997). Naltrexone and alcohol dependence: Role of subject compliance. Archives of General Psychiatry, 54, 737-742.
31. Walsh, S.L., Preston, K.L., Bigelow, G.E., & Stitzer, M.L. (1995). Acute administration of buprenorphine in humans: Partial agonist and blockade effects. Journal of Pharmacology and Experimental Therapeutics, 274, 361-372.
32. Whitworth, A.B., Fischer, F., Lesch, O.M., Nimmerrichter, A., Oberbauer, H., Platz, T., et al. (1996). Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet, 347, 1438-1442.
33. Wilkerson, D., Migas, N., & Slaven, T. (2000). Outcome-oriented standards and performance indicators for substance dependence rehabilitation programs. Substance Use & Misuse, 35(12-14), 1679-1703.
34. Zweben, J.E., & Payte, J.T. (1990). Methadone maintenance in the treatment of opioid dependence. A current perspective. Western Journal of Medicine, 152, 588-599.